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next big thing in solid tumor therapeutics
Karie Runcie1, Daniel R. Budman1,2, Veena John1,2 and Nagashree Seetharamu1,2*

Abstract
Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the
treatment of Non-Hodgkin’s Lymphoma. Monoclonal antibodies against cancer antigens have been successful
strategies for only a handful of cancer types due to many reasons including lack of antibody specificity and
complex nature of tumor milieu which interfere with antibody efficacy. Polyspecific antibodies are promising class
of anti-cancer agents which can be directed at multiple tumor antigens to eradicate tumor cells more precisely and
effectively. They may overcome some of these limitations and have already changed treatment landscape for some
malignancies such as B cell acute lymphoblastic leukemia. Pre-clinical studies and early phase clinical trials have
demonstrated that this approach may be an effective strategy even for solid tumors. This review focuses on the
development of bispecific and trispecific antibody therapy for the treatment of solid tumor malignancies and
highlights the potential they hold for future therapies to come.
Keywords: Bispecific antibody, Trispecific antibody, Immunotherapy, Solid tumor

Background
Cancer remains the second leading cause of death in the
United States, with lung cancer being the leading cause
of cancer deaths, followed by breast cancer in women
and prostate cancer in men (Siegel 2017). Over the past
few decades, new and targeted therapies have contributed to significant improvements in the 5-year relative
overall survival rate for all cancers combined, most
prominent in hematopoietic and lymphoid malignancies
(Siegel 2017). An integral part of this revolution has
been development of monoclonal antibodies in the
1970s. Rituximab, a genetically engineered chimeric antibody against the CD 20 antigen found on the surface of
B cells, was the first monoclonal antibody approved by
the Food and Drug Administration in 1997 for the treatment of Non-Hodgkin’s lymphoma (Leget and Czuczman 1998; White et al. 2000). Since then, the use of
monoclonal antibodies for cancer therapy has evolved to
target different molecules and has expanded treatment
options for solid tumors as well as hematologic malignancies. Despite the excellent tolerability profile and
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efficacy in various cancers, these agents are rarely effective as monotherapies and have several limitations. Activation of alternate molecular pathways, acquired
changes in the tumor milieu, and suboptimal engagement of monoclonal antibodies to their targets are just
some of the drawbacks (Fousek and Ahmed 2015). Recent innovations based upon improvements in protein
engineering have resulted in combining antibodies for
synergistic effect (Henricks et al. 2015; Binyamin et al.
2006); development of antibodies with genetically engineered Fc receptors to achieve higher effector functions
such as antibody-dependent cytotoxicity (Binyamin et al.
2006); and creation of bi-specific and tri-specific antibodies which are capable of binding to multiple targets
(Segal et al. 1999; Mertens et al. 2001). A search of
Pub-Med in February 2018 reveals 2744 articles on
bi-specific antibodies with 1784 mentioning cancer. In
an analogous fashion for tri-specific antibodies, a search
noted 37 articles with 25 mentioning cancer.

Historical review
The concept of using a molecule with more than one
binding site to enhance its biological function actually
dates back to 1961 when two antigen-binding fragments
from different polyclonal sera were combined to form
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bispecific molecules (Nisonoff and Rivers 1961). The
techniques of chemical conjugation of two different
antigen-specific monoclonal antibodies and fusion of
two antibody producing hybridoma cell lines (quadromas) in the 1970s and 1980s took the production of bispecific antibodies to the next level (Staerz et al. 1985;
Karpovsky et al. 1984; Perez et al. 1985). Although some
of these primitive formats showed appreciable activity
against certain malignancies, the vast majority had a dismal therapeutic-risk index. With rapid advances in genetic engineering, the past two decades have seen a
dramatic increase in the production of polyspecific antibodies with more than 120 described formats now in
clinical use or undergoing evaluation in clinical trials
(Spiess et al. 2015). Even though majority of the early
development of polyspecific antibodies was focused on
hematological malignancies, there are several molecules
in clinical development that are directed towards
non-hematological cancers. Our review focuses on clinical development of bi-specific and tri-specific antibodies
directed towards solid tumors.

Advantages and disadvantages of polyspecific
monoclonal antibodies
Polyspecific monoclonal antibodies (PsMabs) are genetically engineered proteins that can simultaneously engage two or more different types of epitopes (Figs. 1a, b
and 2) (Fan et al. 2015; Zhang et al. 2017). They show
several advantages over monoclonal antibodies (Fig. 2)
in that they can: 1) redirect specific polyclonal immune
cells such as T cells and NK cells to tumor cells to enhance tumor killing, 2) simultaneously block two different pathways with unique or overlapping functions in
pathogenesis, 3) potentially increase binding specificity
by interacting with two different cell surface antigens instead of one, and 4) reduce cost in terms of development
and production when compared to multiple single based
antibodies used in combination therapy or compared to
the production of CAR-T cells. The advantages and disadvantages of polyspecific antibodies are tabulated in
Table 1.
PsMab formats
Bispecific antibodies with ability to engage two different
antigens are the most commonly used PsMabs. Since the
initial experiments to produce BsMabs (Holliger and
Winter 1993), the products have undergone major transformation (Brinkmann and Kontermann 2017) and have
proved useful in cancer diagnosis, imaging, and treatment. The differences in the first generation BsMabs
and the newer molecules are tabulated in Table 2. The
components of polyspecific antibodies used today range
from full antibody structures to fragments, with creation
of structures only limited by the vision of the molecular
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chemist, patenting rules, physiochemical constraints,
and clinical utility. Some of the BsMab manufactured
today include bispecific small molecule-antibody conjugates, chemical hetero-conjugates, and protein genetic
engineering involving recombinant DNA technology
(Spiess et al. 2015; Brinkmann and Kontermann 2017).
The most studied structures are shown in Fig. 1a and b.
In general, these bispecific antibodies are divided into
two major classes: IgG like bispecific antibodies which
carry an Fc region and therefore retain Fc-mediated effector functions and the non-IgG like formats which rely
entirely on their antigen binding capacity to exert therapeutic effects. The differences between these two classes
are highlighted in Table 3. Fc mediated effector functions include antibody-dependent cell mediated toxicity
(ADCC), antibody dependent cellular phagocytosis
(ADCP), complement-dependent cyototoxicity, and the
binding of the molecules to the neonatal Fc receptor
(FcRn) which protects IgG from degradation and increases the molecular half-life (Fan et al. 2015).
In the past, IgG-like BsAbs were created by chemical
conjugation or hybridoma techniques. These were cumbersome, time-consuming procedures and resulted in
creation of nonfunctional molecules through random assembly of different heavy and light chains in addition to
intended bispecific antibodies (Staerz et al. 1985). These
shortcomings can be improved using recombinant DNA
technology. For example, bispecific tetravalent molecules
such as dual-variable-domain immunoglobulin (DVD-Ig)
can now be produced by combining two target-binding
monoclonal antibodies via naturally occurring linkers
and optimizing yield of viable molecules through advanced recombinant DNA techniques (Spiess et al.
2015). The simultaneous binding of antigen to all variable domains in dual variable domain immunoglobulin
(DVD-Ig) provide a higher specific binding capacity
which could be used in targeting low abundance proteins such as cytokines (Sedykh et al. 2018) and potentially also allow the drug to be dosed less frequently.
Recombinant techniques have also led to the creation
of small fragment molecules by combining single chain
variable fragments from two different monoclonal antibodies to form bivalent bispecific “antibodies” ranging in
size from 50 to 60 kDa (Kontermann 2012). Some examples of these are the bispecific T cell engager (BiTE), tandem single chain variable fragments (taFvs), diabodies
(Dbs), single chain diabodies (scDbs), and triplebodies.
Due to their small size, these scFV based antibody fragments have high tumor specificity and tumor penetration. However, their small size also limits serum
half-lives which could potentially limit efficacy and increase cost by requiring repetitive dosing (Zhang et al.
2017). By fusing these antibody fragments with albumin
or proteins that bind albumin, the serum half-life can be

Runcie et al. Molecular Medicine (2018) 24:50

Page 3 of 15

a

b

Fig. 1 a: Some formats of IgG –like bispecific antibodies and a trispecific antibody. (A) Quadroma created by combining the light and heavy
chains of two different monoclonal antibodies resulting in two antigen binding sites aimed at different tumor antigens eg. Catumaxomab (B)
Two antibody chains with engineered CH3 domain to create a “knob” in one heavy chain and a “hole” in the other to promote
heterodimerization. This allows only specific pairing of heavy chains to reduce mispairing. (C) Variable domains of two mABs fused to create a
dual- specific antibody (D) CrossMab exchanging of the CH1 domain of one heavy chain with the constant domain of the corresponding light
chain for better light chain pairing (E) Bispecific antibody with two unique antigen-binding sites and a chemotherapy payload attached to the
constant domain (F) Trispecific antibody engineered to bind to three different ligands on tumor cell. b: Some formats of bispecific antibody
fragments and fusion proteins. (A) scFvs – Combination of the variable region of one light chain with the variable region of one heavy chain
fragment is the basic element for antigen binding. (B) bi-Nanobody- Combination of two different single variable heavy chain domains which are
able to bind different tumor antigens. (C) BiTE- Tandem single chain variable fragments from different antibodies joined by a flexible peptide
chain. (D) Diabody – Bivalent molecules composed of two chains each comprising a variable light chain and variable heavy chain domain, either
from the same or different antibodies. (E) TandAbs - Two pairs of variable light chain and variable heavy chain domains are connected in a single
polypeptide chain to form a tetravalent tandAb. (F) DNL-Fab3 – Trivalent bispecific antibody composed of three Fab fragments joined by the
utilization of the specific interaction between the regulatory subunits of cyclic adenosine monophosphate (cAMP)-dependent protein kinase A
(PKA) and the anchoring domains of A kinase anchoring proteins (AKAP). (G) DART – Two polypeptide chains derived from the variable heavy
chain from one molecule linked to a variable light chain of another molecule. (H) DART-Fc - DARTs with a Fc fragment designed to prolong
serum retention time. (I) scFv-HAS-scFV- Association of two single chain variable fragments through modified dimerization domains

prolonged by five or six times (Sedykh et al. 2018).
Other methods such as PEGylation, Fc fragment fusion, and multimerization are also being explored to
extend antibody serum half-life (Fan et al. 2015). The
major advantages and disadvantages of IgG – like bispecific antibodies and bispecific antibody fragments
are listed in Table 3.

The BiTE warrants special mention as one of the binding sites is engineered to bring an effector cell (T-cell or
NK cell) into the proximity of the tumor cell to enhance
antitumor effect (Fig. 2). This function results in more
effective tumor cell lysis relative to other bispecific formats and monoclonal antibodies (Yang et al. 2016). In
the case of T-cells, the target site for binding is
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Fig. 2 Schematic showing different formats of immunotherapy binding to the antigen on the tumor cell: (1) monoclonal antibody, (2) bispecific
antibody, (3) trispecific antibody, (4) bispecific T cell engager made from two single chain antibody fragments, and (5) CAR T cell therapy which is
comprised of light chain and heavy chain variable fragments joined by a flexible linker

commonly CD3. The bi-specific binding of a white cell
to the target mimics the action for an activated white
cell against its target (Offner et al. 2006). This functionality of bispecific antibody which can use non-HLA restricted white cells without in vitro expansion was
described in 1985 but could not be exploited until
Table 1 Advantages and disadvantages of polyspecific
antibodies over monospecific antibodies
Advantages

Disadvantages

Amenable for large scale
production

Hetero-dimerization of chains may
make the molecule inefficient; early
methods had low production
yields

More efficient binding to target

Steric inhibition of engaging sites

Able to engage T cell or NK cells
(MHC agnostic) by a cell
combining site

Potential antigenic cytokine release
syndrome

Stability

Small molecules can be rapidly
cleared; larger ones may aggregate;
potential immunogenicity

Not patient specific; target specific

Tight white cell binding may
change bio-distribution

Can be a carrier of radioisotope or
chemotherapy

Potential poor internalization of
molecule if combined with
cytotoxic agent

Can be used for imaging

Need for external epitope

Can serve as an immune enhancer Affinity for target epitope and
effector cell critical
Can be encapsulated in a
liposome

Large molecules have less intratumoral penetration.

Can be combined with other
immunological agents

May enhance toxicity if combined
with classical immunological
agents

Bystander effect

recently (Staerz et al. 1985). Another advantage of this
approach is a bystander effect on adjacent cells which
may be of value in a tumor with heterogeneous expression of target epitope (Ross et al. 2017). It was recently
noted in a study looking at the bio-distribution of a
T-cell dependent bi-specific antibody in a murine model
of human HER2 breast cancer that the binding affinity
for the white cell can determine whether or not the
bi-specific antibody/white cell combination can reach
the target site or becomes trapped in lymphatic organs
(Mandikian et al. 2018). Hence, negative studies with
bi-specific antibodies may be in part due to lack of target
cell engagement due to poor distribution.
The diabody format which has two variable domains
of two different antibodies connected by two linkers has
more stability than BiTEs but the linkers restrict the mobility of the antigen binding sites limiting antigen recognition (Fan et al. 2015). DART bispecific antibodies,
created by engineering two Fv fragments with the variable heavy chain portion exchanged with one another,
are larger than BITEs and show better serum stability
(Zhang et al. 2017). The Dock-and-Lock (DNL) recombinant method (Fig. 1b) creates multivalency and multifunctionality with bispecific antibody fragments (Rossi et
al. 2006). These later generation formats such as BiTE,
dual-affinity re-targeting antibodies (DART) antibodies,
tandem diabodies appear to potently eliminate targets
expressing their tumor associated antigen (TAA) in the
absence of costimulatory models or IL-2 pre-activated T
cells (Zhukovsky et al. 2016).

PsMab in clinical use
Currently, there is only one bi-specific antibody approved for cancer therapy. The first bispecific antibody
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Table 2 Production, limitations, and examples of first and
subsequent generations of BsMab
EarlierBsMab

NewerBsMab

Produced by oxidative
recombination, chemical
cross-linking, and enzymatic
digestion of desired antibodies
to yield Fab fragments which
are then combined via
bifunctional reagents
to form a heterodimer21,22.

Produced by advanced techniques
such as controlled Fab-arm
exchange (cFAE), improvised
somatic fusion of two hybridoma
cell lines (quadroma), small
molecule-antibody conjugation,
genetic engineering using
molecular cloning technology20.

Inability to produce large
quantities

Shorter processing time and ability
to produce in large-scale.

Rapid destruction of murine
antibody fragments

Stability and longer half-life.

Difficult to purify

> 90% pure
23

Examples: MDX-210 (targeting
Her2, and CD 64 or FcyRI which is
expressed on monocytes, macrophages and activated neutrophils;
MDX-447 24(targeting EGFR and
CD 64;
HRS-3/49- Targeting CD 30 on
Reed Sternberg cells in Hodgkin
lymphoma and FcyRIII or CD 16 on
natural killer cells and
macrophages.

Examples: Catumaxomab and
Solitomab (targeting EpCAM
expressed on breast, ovarian and
other cancer cells as well as CD3
on T cells-bispecific T cell engager
or BiTE)23,26,27; Blinatumomab28
(binding to both CD19 on B cell
cells and CD3 on T cells).

to enter clinic, Catumaxomab was approved by European Union for use in malignant ascites in 2009 (Seimetz 2009). Catumaxomab is a trifunctional antibody
produced by a rat-mouse quadroma cell with affinities to
CD3 antigen on cytotoxic T cells and epithelial cell adhesion molecule (EpCAM) which is a type 1 transmembrane glycoprotein associated with malignant ascites and
effusions and expressed on the majority of epithelial cancers (Linke et al. 2010; Seimetz 2011). The approval was
based on studies showing the efficacy of intraperitoneal
Table 3 Comparing different formats of bispecific antibodies
Antibody
format

Advantages

Disadvantages

IgG- like
bispecifc
antibodies

Longer half life

Fc region more
immunogenic

Fc domain facilitates
efficient purification
Fc domain able to trigger
antibody dependent cell
mediated toxicity,
complement dependent cell
mediated toxicity

Bispecific
Antibody
Fragments

High tumor specificity
Good tissue penetration
Small formats can allow close
contacts between effector
and target cells forming
efficient immune synapses
not requiring co-stimulatory
molecules
Easy to manufacture

Small size make them
prone to elimination i.e.
shorter half-life

administration of Catumaxomab in improving symptoms
and signs of malignant ascites and reducing the need for
paracentesis (Heiss et al. 2010; Frampton 2012). A positive trend of overall survival in patients with malignant
ascites associated with epithelial cancers was also noted
in a prospective randomized trial (Heiss et al. 2010;
Frampton 2012) and there was demonstrable activity in
platinum refractory epithelial ovarian cancer (Baumann
et al. 2011). The drug was deemed safe for use in outpatient setting in patients with malignant ascites secondary to gynecological tumors including epithelial ovarian
cancer and metastatic breast cancer (Kurbacher et al.
2015). Although Catumaxomab showed promising results, it was taken off the market in 2014 due to financial
reasons. Its approval was subsequently withdrawn in
2017 (No Title. https://neovii.com/neovii-completes-marketing-authorisation-withdrawal-of-removab-in-the-european-union/ n.d.).
The bi-specific antibody Blinatumomab was approved by
the US FDA in December 2014 for the treatment of acute
B-cell acute lymphoblastic leukemia (ALL). Blinatumomab
is a novel bi-specific T cell engager which binds sites for
both CD19 (antigen expressed on all stages of B cell
lineage) and CD3 T cell receptor complex, leading to T cell
proliferation and activation resulting in target cell (lymphoblast) apoptosis. Unlike catumaxomab, which uses large
IgG-like bi-specific antibodies with Fc regions, blinatumomab was created by the fusion of two single chain variable
fragments (scFv) connected in a flexible manner through a
peptide linker (Newman and Benani 2016). It has been
shown to induce durable responses in patients with B cell
malignancies and was quickly approved after phase II trial
of adult patients with Philadelphia-chromosome-negative
relapsed or refractory B-precursor ALL, 43% (81 out of
189) of patients reached the primary endpoint of complete
hematological response (Topp et al. 2014). A subsequent
multi-institutional phase 3 trial evaluated blinatumomab to
standard-of-care chemotherapy in heavily pre-treated B-cell
precursor ALL confirmed excellent activity of the drug in
these patients with improved outcomes, including overall
and progression-free-survivals (Kantarjian et al. 2017).

Other agents including those in development
The clinical success of these engineered antibodies has
ushered in a phase of rapid development of new agents
for the treatment of various solid tumor malignancies.
Many tyrosine kinase receptors which are integral in
regulating the pathway of cell growth, cell differentiation, cell migration, and cell death are prime targets for
most of these molecules (Yu et al. 2017; Kalyankrishna
and Grandis 2006; Loibl and Gianni 2017; Ooi et al.
2004; Shinojima et al. 2003). A few examples are
highlighted here and a detailed log of ongoing clinical
trials is presented in Table 4.
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Table 4 Recent clinical trials involving the use of bispecific antibodies in solid tumor malignancies
Drug name

Antibody type

Sponsor

Target
antigens

Indication

Status

Clinical trials
identifier

Selicrelumab
Vanucizumab
Bevacizumab

CrossMab

Hoffmann-La
Roche

Ang2, VEGF Phase I

Advanced/ Metastatic Solid
Tumors

Recruiting

NCT02665416

rM28, autologous
PBMCs

Tandem ScFv

University Hospital CD28,
Tuebingen
HMV-MMA

Phase I/Phase
II

Stage III/IV metastatic
melanoma

Completed NCT00204594

Indium labeled
IMP-205xm734

IgG type
bispecific
antibody

Radboud
University

CEA

Phase I

Colorectal carcinoma

Completed NCT00185081

Obinutuzumab,
RO6958688

IgG type T cell
bispecific
antibody

Hoffmann-La
Roche

CEA, CD3

Phase I

Locally advanced or Metastatic
Solid Tumors

Active, not NCT02324257
recruiting

MEDI 565

BITE

MedImmune LLC

CEA, CD3

Phase I

Gastrointestinal
Adenocarcinomas

Completed NCT01284231

Anti-CEA x antiDTPA

Fusion of two
Fab fragments

Nantes University
Hospital

CEA, DTPA

Phase II

Medullary Thyroid Carcinoma

Completed NCT00467506

anti-CEA x antiHSG TF-2

Dock and lock
bispecific
antibody

Garden State
Cancer Center at
the Center for
Molecular
Medicine and
Immunology

CEA, HSG

Phase I

Detection of Colorectal
Carcinoma

Unknown

TF2 antibody/
68Ga-IMP-288

Gallium labeled
Dock and lock
bispecific
antibody

Nantes University
Hospital

CEA, HSG

Phase II

Metastatic Colorectal Cancer

Completed NCT02587247

TF2–68 Ga-IMP288

Gallium labeled
Dock and lock
bispecific
antibody

Nantes University
Hospital

CEA, HSG

Phase I/Phase
II

HER2 negative Breast
Carcinoma expressing CEA

Active, not NCT01730612
recruiting

Centre René
Gauducheau

CEA, HSG

Phase I/Phase
II

Small Cell Lung Cancer
CEA-Expressing NSCLC

Completed NCT01221675

Anti- CEA x AntiDock and lock
HSG TF2, Radiation bispecific
antibody

Development
stage

NCT00895323

TF2 and 68 GaIMP-288

Gallium labeled
Dock and lock
bispecific
antibody

Nantes University
Hospital

CEA, HSG

Phase I/
Phase II

Medullary Thyroid Carcinoma

Completed NCT01730638

TF-2, IMP-288 labeled with In111
and Lu177

Dock and lock
bispecific
antibody

Radboud
University

CEA,
Lu177labeled
peptide

Phase I

Colorectal cancer

Completed NCT00860860

AMG 757

BITE

Amgen

DLL3

Phase I

Small Cell Lung Cancer

Recruiting

NCT03319940

NOV1501

IgG type
bispecific
antibody

National
OncoVenture

DLL4, VEGF Phase I

Advanced Solid Tumors

Recruiting

NCT03292783

OMP-305B83

IgG type
bispecific
monoclonal
antibody

OncoMed
Pharmaceuticals

DLL4, VEGF Phase I

Metastatic Colorectal Cancer

Recruiting

NCT03035253

OMP-305B83

IgG type
bispecific
monoclonal
antibody

OncoMed
Pharmaceuticals

DLL4, VEGF Phase I

Previously Treated Solid Tumors Active, not NCT02298387
recruiting

OMP-305B83,
Paclitaxel

IgG type
bispecific
monoclonal
antibody

OncoMed
Pharmaceuticals

DLL4, VEGF Phase I

Ovarian, Peritoneal or Fallopian
Tube Cancer

Recruiting

NCT03030287

EEDVsMit

Nanocell coated Dr. David Ziegler
with IgG type

EGFR

Refractory solid or CNS tumors
expressing EGFR

Recruiting

NCT02687386

Phase I

Runcie et al. Molecular Medicine (2018) 24:50
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Table 4 Recent clinical trials involving the use of bispecific antibodies in solid tumor malignancies (Continued)
Drug name

Antibody type

Sponsor

Target
antigens

Development
stage

Indication

Status

Clinical trials
identifier

NCT02766699

bispecific
antibody and
mitoxantrone
payload
EGFR (V)- EDVDox

Nanocell coated Engeneic Pty
with IgG type
Limited
bispecific
antibody and
doxorubicin
payload

EGFR

Phase I

Recurrent Glioblastoma
Multiforme

Recruiting

TargomiRs

Nanocell coated Asbestos Disease
with IgG type
Research
bispecific
Foundation
antibody
containing
microRNA

EGFR

Phase I

Recurrent malignant pleural
mesothelioma
Non-small cell lung cancer

Completed NCT02369198

MDX447

IgG type
bispecific
antibody

DartmouthHitchcock Medical
Center

EGFR

Phase I

Brain and Central Nervous
System Tumors

Completed NCT00005813

Anti-CD3x antiEGFR bispecific
armed activated T
cells (BATs),
Aldesleukin,
Sargramostim

T cells
preloaded with
IgG type
bispecific
antibody

Barbara Ann
Karmanos Cancer
Institute

EGFR, CD3

Phase I/
Phase II

Locally advanced, metastatic, or Active, not NCT02620865
recurrent pancreatic cancer
recruiting

EGFR BATs

T cells
preloaded with
IgG type
bispecific
antibody

University of
Virginia

EGFR, CD3

Phase I/
Phase II

Locally advanced and
metastatic pancreatic cancer

Recruiting

NCT03269526

Anti-CD3 x AntiEGFR BATs with radiation and
temozolomide

T cells
preloaded with
IgG type
bispecific
antibody

University of
Virginia

EGFR, CD3

Phase I

Glioblastoma Multiforme

Recruiting

NCT03344250

JNJ-61186372

IgG1 type
bispecific
antibody

Janssen Research
and Development
LLC

EGFR, cMet Phase I

Advanced non-small cell lung
cancer

Recruiting

NCT02609776

MCLA-158

IgG1 bispecific
antibody

Merus N.V.

EGFR, LGR5 Phase I

Metastatic Colorectal Cancer
and select advanced solid
tumors

Recruiting

NCT03526835

Catumaxomab

Trifunctional IgG AGO Study Group
type antibody

EpCAM,
CD3

Phase II

Ovarian cancer, Fallopian Tube
Neoplasms, Peritoneal
Neoplasms

Completed NCT00189345

Catumaxomab

Trifunctional IgG Neovii Biotech
type antibody

EpCAM,
CD3

Phase II/Phase Malignant ascites
III
EpCam positive tumors

Completed NCT00836654

Catumaxomab

Trifunctional IgG Neovii Biotech
type antibody

EpCAM,
CD3

Phase II

Gastric Adenocarcinoma after
neoadjuvant chemotherapy
and curative resection

Completed NCT00464893

Catumaxomab

Trifunctional IgG Neovii Biotech
type antibody

EpCAM,
CD3

Phase II

Gastric Adenocarcinoma after
curative resection

Completed NCT00352833

MT110

BITE

Amgen Research
(Munich)

EpCAM,
CD3

Phase I

Gastric Cancer or
Completed NCT00635596
Adenocarcinoma of the Gastroesophageal Junction, Colorectal
Cancer, Breast Cancer,
Hormone-Refractory Prostate
Cancer, Ovarian Cancer

GD2Bi-aATC

T cells
preloaded with

Barbara Ann
Karmanos Cancer

GD2

Phase I/ II

Desmoplastic small round cell
tumor, Disseminated

Recruiting

NCT02173093
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Table 4 Recent clinical trials involving the use of bispecific antibodies in solid tumor malignancies (Continued)
Drug name

Antibody type

Sponsor

Target
antigens

Development
stage

IgG type
bispecific
antibody

Institute

MGD007

DART

MacroGenics

gpA33,
CD3

Phase I

MGD007 and
MGA012

DART

MacroGenics

gpA33,
CD3, PD-1

ERY974

IgG4 bispecific T Chugai
cell-redirecting Pharmaceutical
antibody

MM-111

Bispecific
antibody fusion
protein

MM-111,
Herceptin

Indication

Status

Clinical trials
identifier

Relapsed/Refractory Metastatic
Colorectal Cancer

Recruiting

NCT02248805

Phase I/
Phase II

Relapsed/ Refractory Metastatic
Colon Cancer

Recruiting

NCT03531632

GPC3, CD3

Phase I

Solid Tumors

Recruiting

NCT02748837

Merrimack
Pharmaceuticals

HER2

Phase I

HER2 Amplified Solid Tumors
Metastatic Breast Cancer

Completed NCT00911898

Bispecific
antibody fusion
protein

Merrimack
Pharmaceuticals

HER2

Phase I

Refractory HER 2 Amplified
Heregulin Positive Breast
Cancer

Completed NCT01097460

ZW25

IgG type
bispecific
antibody

Zymeworks Inc.

HER2

Phase I

Unresectable and/or metastatic Recruiting
HER2 positive cancers

NCT02892123

Her2 BATs,
Recombinant IL-2

T cells
preloaded with
IgG type
bispecific
antibody

Yi Miao

HER2

Phase I

Her2 Positive Neoplasms of
Digestive System

Unknown

NCT02662348

MCLA-128

IgG type
bispecific
antibody

Merus N.V.

HER2 and
HER3

Phase I/Phase
II

Malignant solid tumor
Breast cancer
Gastric cancer
Ovarian cancer
Endometrial cancer
Non- Small cell lung cancer

Recruiting

NCT02912949

HER-2 BATs with
Pembrolizumab

T cells
preloaded with
IgG type
bispecific
antibody

University of
Virginia

HER2
specific
antibody
armed
activated T
cell
infusions

Phase I/Phase
II

Metastatic Breast Cancer

Recruiting

NCT03272334

Anti-CD3 x HER2BATs

T cells
preloaded with
IgG type
bispecific
antibody

Barbara Ann
Karmanos Cancer
Institute

HER2, CD3

Phase II

Metastatic Castration Resistant
Prostate Cancer

Recruiting

NCT03406858

GBR1302

BEAT-bispecific
antibody with
heavy chain,
light chain and
Fc-scFv

Glenmark
Pharmaceuticals
S.A.

HER2, CD3

Phase I

HER2 Expressing Solid Tumors

Recruiting

NCT02829372

HER2- BATs,
Pembrolizumab

T cells
preloaded with
IgG type
bispecific
antibody

University of
Virginia

HER2, CD3,
PD-1

Phase I/
Phase II

Metastatic Breast Cancer

Recruiting

NCT03272334

MCLA-128/
trastuzumab/
chemotherapy,
MCLA-128, endocrine therapy

IgG type
bispecific
antibody

Merus N.V.

HER2, ER

Phase II

Metastatic Breast Cancer

Not yet
recruiting

NCT03321981

IMCgp100

TCR fused to

Immunocore Ltd.

HLA A2,

Phase I

Advanced Malignant

Completed NCT01211262

neuroblastoma, Metastatic
Osteosarcoma, Recurrent
Neuroblastoma, Recurrent
Osteosarcoma
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Radioimmunotherapy

Radioimmunoscintigraphy (RIS) and radioimmunotherapy (RIT) use the antibody specificity of tumor-based
antigens in conjunction with emitted radiation from
suitable radioisotopes to image malignancies (RIS) for
diagnostic and treatment purposes. The radioantibody is
injected intravenously and distributes to the antigen
binding site on tumor cells where the radionuclide delivers the tumoricidal dose to the tumor mass (Larson et
al. 2015). RIT allows the delivery of radiation doses to
multiple dispersed sites simultaneously which makes it
effective in killing tumors that have already metastasized
to multiple organs (Yang et al. 2016). RIT has traditionally proven efficacious in hematological malignancies
such as non-Hodgkin’s lymphoma, which are characterized as more radiosensitive than solid tumor malignancies (Song and Sgouros 2011). Solid tumor malignancies
require higher radiation doses to induce tumor cell
apoptosis leading to increased adverse effects to radiosensitive areas such as the kidney, lung, and bone marrow. However, intra-compartmental RIT, the addition of
chemotherapy to RIT, and the use of alpha emitters are
being used to improve the therapeutic index of RIT in
solid tumors with less toxicity (Larson et al. 2015). One
limitation of conventional radioimmunotherapy is the
prolonged radiation exposure of nontarget normal tissues and poor tumor to normal tissue radiation absorbed
dose ratios. The development of pre-targeted radioimmunotherapy (PRIT), which first allows tumor specific
antibodies to distribute to the tumor antigen site
followed by the administration of a small radioactive
agent with high affinity for the tumor antibody, limits
the accumulation of radiation in non-target sites (Larson
et al. 2015). Several bispecific antibodies have been designed and used in these capacities as pre-targets for
RIT in addition to providing high specificity binding
sites for both the tumor antigen and the radioactive material promoting tumor cell death. A trivalent bispecific
antibody, TF12, which targets epithelial glycoprotein − 1
antigen (EGP-1 or TROP-2) and histaminesuccinyl-glycine (HSG), when used with lutetium-177 labeled peptide for PRIT in prostate cancer demonstrated
effective targeting and permeability in mice pre-clinical
studies (van Rij et al. 2014). There are many ongoing
clinical trials examining the role of bispecific antibodies
in RIT for solid tumors eg. colorectal carcinoma
[NCT00185081], [NCT02587247], [NCT000860860],
HER2 negative breast cancer [NCT01730612], and lung
cancer [NCT01221675] (No Title. clinicaltrials.gov n.d.).
Targeting carcino-embryonic antigen (CEA)

Trials are studying the bi-specific targeting of CD3 in
combination with the tumor antigen, CEA, which is highly
expressed in gastrointestinal malignances, non-small cell

Page 9 of 15

lung cancer (NSCLC), breast cancer, uterine, and bladder
cancers [NCT02324257], [NCT01284231] (No Title. clinicaltrials.gov n.d.). CEA is also used as a target in the DNL
TF2 antibody which divalently binds CEA and monovalently binds the peptide-hapten histamine-succinyl-glycine
(HSG). Similar to the TF12 format described above, the
TF2 antibody first binds to CEA, then an HSG peptide
carrying a radionuclide is given which can be used for imaging of the tumor or to deliver radiation to the tumor
cells [NCT00895323], [NCT01730612], [NCT01221675]
(No Title. clinicaltrials.gov n.d.). In a recent study comparing pre-targeted immunoPET, which uses TF2 and
Ga-IMP-288, to conventional 18FDG PET, immunoPET
was more sensitive than 18FDG PET (67% versus 31%) for
detection of colonic liver lesions in an orthotopic murine
model (Foubert et al. 2018).

Targeting MET and EGFR

The receptor tyrosine kinase, MET, is one of the most
commonly dysregulated oncogenes in non-small cell
lung cancer (NSCLC) and met gene amplification has
been shown to be a major mechanism in which cancers
develop resistance to EGFR inhibitors (Bean et al. 2007).
Phase III studies which solely targeted MET have failed
to show clinical benefit in NSCLC (Baldacci et al. 2017)
but dual targeting of MET and EGFR using bispecific
antibodies is promising (Tang et al. 2008; Castoldi et al.
2013) and is currently being explored in NSCLC
[NCT02609776] (No Title. clinicaltrials.gov n.d.) and
other solid tumors [NCT02221882] (No Title. clinicaltrials.gov n.d.). However, other studies such as the MEHGAN study have provided definitive clinical evidence
refuting this hypothesis (Fayette et al. 2016).
EGFRvIII, a rearranged variant of EGFR frequently
expressed and associated with poor prognosis in Glioblastoma Multiforme (GBM), and also found in breast
and lung carcinoma, was recently found to be expressed
in glioma stem cell lines (Emlet et al. 2014). In vivo, a
bi-scFv binding CD3 and EGFRvIII, has shown efficacy,
specificity, and potency in mice with established EGFRvIII intra-cerebral tumors and may be promising in this
highly fatal and difficult to treat malignancy (Gedeon et
al. 2013). Another novel method of targeting EGFR, designed by Engeneic, are bacteria derived nanocells coated
with bispecific antibodies which can be packaged with
chemotherapy such as doxorubicin or mRNA. The bispecific antibody coating allows specificity to certain
tumor antigens such as EGFR and limits toxicity to normal cells. The chemotherapy or mRNA payload is released directly into the tumor cell increasing the potency
of the therapeutic agent (Shah et al. 2016).There are several phase I trials examining the efficacy of these molecules in EGFR positive CNS tumors as well as solid
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Table 4 Recent clinical trials involving the use of bispecific antibodies in solid tumor malignancies (Continued)
Drug name

Antibody type

Sponsor

Target
antigens

Development
stage

Indication

Status

Clinical trials
identifier
NCT03440437

ScFv

CD3

FS118

IgG type
F-star Delta
bispecific
Limited
antibody with
Fc capable of
antigen binding

LAG3, PDL1

Phase I

Advanced Malignancies

Recruiting

LY3164530

IgG4 antibody
combined with
scFV

Eli Lilly and
Company

MET and
Anti- EGFR

Phase I

Metastatic neoplasm including
NSCLC

Completed NCT02221882

Anti-CD3-MUC1
and Activated CIK

Fusion of two
Fab fragments

Benhealth
Biopharmaceutical
(Shenzhen) Co.,
Ltd

MUC1, CD3 Phase II

Advanced liver cancer

Recruiting

NCT03146637

Activated CIK with Fusion of two
CD3-MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced liver cancer

Recruiting

NCT03484962

Activated CIK with Fusion of two
CD3-MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced gastric cancer

Recruiting

NCT03554395

Activated CIK with Fusion of two
CD3-MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced kidney cancer

Recruiting

NCT03540199

Activated CIK with Fusion of two
CD3- MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced breast cancer

Recruiting

NCT03524261

Activated CIK with Fusion of two
CD3- MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced lung cancer

Recruiting

NCT03501056

Activated CIK with Fusion of two
CD3-MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced colorectal cancer

Recruiting

NCT03524274

Activated CIK with Fusion of two
CD3-MUC1
Fab fragments

Fuda Cancer
Hospital,
Guangzhou

MUC1, CD3 Phase II

Advanced pancreatic cancer

Recruiting

NCT03509298

PF-06671008

DART

Pfizer

P-Cadherin, Phase I
CD3

Advanced Solid Tumors

Recruiting

NCT02659631

XmAb20717

Fc engineered
bispecific
antibody

Xencor

PD1, CTLA4 Phase I

Selected Advanced Solid
Tumors

Recruiting

NCT03517488

MGD013

DART

MacroGenics

PDL-1,
LAG-3

Phase I

Unresectable or Metastatic
Neoplasm

Recruiting

NCT03219268

ES414

scFv domains
linked to Fc of
IgG1

Aptevo
Therapeutics

PSMA, CD3

Phase I

Metastatic Castration Resistant
Prostate Cancer

Recruiting

NCT02262910

BAY2010112

BITE

Bayer

PSMA, CD3

Phase I

Castration Resistant Prostate
Cancer

Active, not NCT01723475
recruiting

XmAb18087

Fc engineered
bispecific
antibody

Xencor

SSTR2, CD3 Phase I

Advanced Neuroendocrine
Tumor and Gastrointestinal
Stromal Tumors

Recruiting

tumors [NCT02766699, NCT02687386] (No Title. clinicaltrials.gov n.d.).
Targeting EpCAM

In addition to catumaxomab described above, many
other molecules targeting EpCAM have been explored

Melanoma

NCT03411915

in clinical trials. In vitro studies showed that Solitomab
(MT110), which binds CD3 and targets EpCAM, increased the sensitivity of tumor cells to cytotoxic T cell
death in multiple EpCAM positive ovarian and endometrial cancer cell lines including ovarian carcinosarcoma
and primary uterine serous papillary carcinoma (Bellone
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et al. 2016; English et al. 2014). An open- label
multi-center dose escalation phase I study was completed in 2015 but the results have not yet been published [NCT00635596] (No Title. clinicaltrials.gov n.d.).
Targeting the HER 2

Ertumaxomab, a trifunctional bispecific targeting HER/
neu, CD3, and Fc receptors showed radiographically
confirmed clinical response and safety in phase I trials
with metastatic breast cancer patients and promising
early results of phase II (Haense et al. 2016; View et al.
2008). The phase II clinical trial however was terminated
by the sponsor for financial reasons. A phase I/II trial is
currently recruiting patients to study the potential effects of MCLA-128 which bi-specifically targets HER2
and HER3 in HER 2 positive breast cancer and other
malignant solid tumors [NCT02912949] (No Title. clinicaltrials.gov n.d.). Another phase I trial is evaluating the
bispecific targeting of the extracellular domain of HER 2
in HER 2 positive breast cancer with the humanized
antibody ZW25 [NCT02892123] (No Title. clinicaltrials.gov n.d.). While HER2 has already proven to be an
effective target in breast cancer, preclinical studies have
suggested that targeting HER2 and CD3 T cells in metastatic castrate resistant prostate cancer might be an effective strategy (Vaishampayan et al. 2015).
Targeting Mucin-1 (MUC-1)

Muc-1 is a membrane protein found on the surface of
many adenocarcinomas and plays a role in inhibiting the
p53 tumor suppression gene (Wei et al. 2007; Kwak et
al. 2010). Previously monoclonal antibody therapy directed at MUC-1 from normal tissues was ineffective
but recent advancements in targeting tumor Muc1 has
been promising in monoclonal antibody studies and
CAR-T cell directed therapy (Danielczyk et al. 2006;
Posey et al. 2016). Bispecific targeting of MUC-1 and
CD16 to mediate NK cytotoxicity cells to target tumor
cells in xenograft models has shown effective tumor suppression (Li et al. 2018). A novel PD-1 inhibitor induced
cytokine- induced killer cells (CIKs) mixed with an
anti-MUC 1 and anti- CD3 bispecific antibody is currently being investigated in several clinical trials for the
treatment of advanced solid tumor malignancies
[NCT03540199], [NCT03524261], [NCT03501056],
NCT03524274], [NCT03509298] (No Title. clinicaltrials.gov n.d.). The bispecific antibody binds to CD3 on
the CIK and MUC1 on tumor cells, crosslinking the
CIKs and tumor cells promoting effective tumor cell
lysis.
Targeting the prostate-specific membrane antigen (PSMA)

PSMA expressed predominantly in prostate cancer cells
as well as the neovasculature of most solid tumors has

Page 11 of 15

been a common target in prostate cancer patients (Rajasekaran 2005). A bispecific diabody targeting PSMA in
conjunction with antibodies against CD3 has decreased
prostate specific antigen levels, inhibited tumor growth
and prolonged survival in preclinical mouse studies
(Bühler et al. 2008).
Targeting the immune checkpoint molecules

An interesting strategy of simultaneous blockade of immune checkpoint molecules such as cytotoxic
T-lymphocyte antigen-4 (CTLA4) or programmed
death-1 (PD-1) or its ligand (PD-L1) and transforming
growth factor-β (TGF-β), which mediates immune tolerance using a bifunctional antibody-ligand trap was recently reported (Ravi et al. 2018). One such novel DART
bispecific antibody, FS118, which simultaneously inhibits
two checkpoint molecules, PDL-1 and lymphocyte activation gene 3 protein (LAG3) is currently in phase I trial
in patients with advanced solid tumor malignancies
[NCT03440437] (No Title. clinicaltrials.gov n.d.). These
agents may potentially improve the efficacy of checkpoint inhibition in various solid tumors which has traditionally been limited with monotherapy.
Bi and tri-specific T cell and natural killer cell engagers

Innovative techniques to harness natural killer cell in
immunotherapy have introduced the concept of
bi-specific killer cell engagers (BiKEs) and tri-specific
killer cell engagers (TriKEs). BiKEs are created by the fusion of a single chain variable fragment (Fv) against CD
16 (antigen on natural killer cells) and a single-chain Fv
against a tumor associated antigen (Rezvani and Rouce
2015). TriKEs are a combination of a single-chain Fv
against CD16 and two tumor associated antigens. These
molecules directly trigger NK cell activation through CD
16 amplifying NK cell cytolytic activity and cytokine production against various tumor cell antigen targets (Gleason et al. 2012). These drugs are currently being
investigated in preclinical studies and safety remains a
concern with the potential to trigger cytokine cascades
(Tay et al. 2016).
Targeting other tumor associated antigens

Other tumor-associated antigens that have been studied
in monoclonal antibody directed therapy are currently
being investigated for bi-specific therapy. Some of these
promising target antigens are not just tumor markers
but molecules found to be essential in tumor cell survival and proliferation. For example, a bi-specific antibody that targets melanoma- associated chondroitin
sulfate proteoglycan (MCSP) and targets the death receptor 5 (DR5, TRAIL-R2), can selectively and potently
kill melanoma cells. This approach may prove beneficial
in those patients resistant to monoclonal antibody
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therapy (He et al. 2016). rM28, a single chain bispecific
format also targeting a melanoma associated proteoglycan recombinant, in addition to targeting CD28, a
co-stimulatory molecule on T cells, showed tumor cell
killing without the need for additional TCR/ CD3 stimulation (Grosse-Hovest et al. 2003). P- Cadherin, a cell-to
cell adhesion molecule, is upregulated in various solid
tumors and overexpression is associated with poor prognosis in breast, ovarian, endometrial, colorectal cancers,
intrahepatic cholangiocarcinoma, and pancreatic cancer.
Pre-clinical studies of DART antibodies targeting PCadherin and CD3 showed significant regression of solid
tumors in vitro and in vivo in mice (Fisher et al. 2018).
Pfizer is currently conducting a dose escalation study of
this molecule, PF-06671008, in patients with P-Cadherin
expressing NSCLC, CRC, and triple negative breast cancer (TNBC) [NCT02659631] (No Title. clinicaltrials.gov
n.d.). Vascular endothelial growth factor (VEGF) and
Angiopoietin-2 (Ang-2), both essential in tumor angiogenesis and escape, are being studied in various
combination
bispecific
formats
[NCT03035253],
[NCT03292783], [NCT02665416], NCT03030287] (No
Title. clinicaltrials.gov n.d.).
Simultaneous targeting of multiple antigens

Even though most polyspecific antibodies have two binding sites (bispecific), there are many new molecules with
three or four binding sites. For example, Castoldi et al.,
have recently developed a tetravalent Fc containing antibody (tetramab) directed against HER1, HER3, c-MET
and IGF1R with enhanced antitumor effects in a preclinical model (Castoldi et al. 2016).
Other novel applications of PsMab therapy

Another example of how novel approaches may simplify treatment is a recent preclinical study demonstrating elimination of large tumors by in-vivo
production of bispecific antibodies induced by parenterally administered engineered mRNA (Holzinger et
al. 2016). If applicable to humans, the high cost of
immunotherapy could be dropped to levels of more
traditional agents. Another intriguing approach to enhance antitumor effect is the use of a tri-specific antibody with an IL-15 cross linker causing enhanced NK
activity antitumor activity (Schmohl et al. 2016). If
the construct turns out to be non- immunogenic and
has enough drug like properties to allow it to advance
in development, the agent may offer an attractive
treatment for appropriate tumors. The structure of a
typical tri-specific antibody is shown in (Fig. 3).
Chimeric antigen receptor adoptive T cell therapy (CAR-T)

Advances in antibody directed therapy have simultaneously fostered the development of another form of
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Fig. 3 Trispecific antibody. Usually created by using variable domain
genes if specific monoclonal antibodies. In this case, antigen-binding
site 1 is bivalent and engages with an antigen on effector cell,
antigen-binding sites 2 and 3 engage antigens 1 and 2 on
tumor cells

immunotherapy, CAR-T cell therapy. While an in-depth
discussion on this exciting topic is out of scope for this
review article which is focused on polyspecific antibodies, we present a brief review on the topic here and
compare the two forms of immunotherapy. CAR-T cell
therapy consists on removing T cells from patients and
modifying ex vivo using gene transfer to enable expression of specific receptors targeting tumor cells through
an antibody-derived binding domain. Once the T cells
are genetically modified to express the chimeric antigen
receptor, they are infused back into the patients to directly kill the cancer cells (Fig. 2) (Caruana et al. 2014).
Currently, CAR T-cell therapy has demonstrated significant anti-tumor activity in the treatment of
hematological malignancies. Tisagenlecleucel, CAR
T-cell therapy directed at CD19 B- cells, was FDA approved in August 2017 for treatment of pediatric patients with refractory or relapsed B-cell precursor acute
lymphoblastic leukemia (Mullard 2017). Multiple CAR-T
agents are currently in advanced stages of clinical development for various hematological malignancies (Gauthier and Yakoub-Agha 2017). In contrast, the success of
CAR T-cell therapy in solid tumors however has been
limited due to the complex tumor microenvironment
and difficulty finding suitable target antigens (Gauthier
and Yakoub-Agha 2017; Zeltsman et al. 2017). Toxicity
and cost have also been major issues with CAR-T cell
therapy that are being actively discussed in various forums (Gauthier and Yakoub-Agha 2017; Abbasi 2017).
Polyspecific antibodies may offer advantages over
CAR-T cell therapy in a multitude of ways and the major
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differences between the two strategies are tabulated in
(Table 5).
While both monoclonal antibody therapy and CAR
T-cells are antigen specific immunotherapies, CAR T
cells, at present, have to be individually manufactured
for each patient resulting in high cost of production.
Despite this, CAR T-cells exhibit several qualities that
could make them more advantageous than antibody directed tumor therapy. The genetically engineered receptors allow CAR T-cells to recognize tumor cells with low
antigen expression and cause direct lysis of tumor cells
whereas classical monoclonal antibodies need a high
density of tumor antigens to trigger the ADCC or complement cascade (Caruana et al. 2014; Gauthier and
Yakoub-Agha 2017). The new constructs of polyspecific
antibodies also allow enhanced binding to target and in
preclinical models have significantly enhanced anticancer activity compared to monoclonal antibodies (Mazor
et al. 2017). Another significant advantage of CAR-T
cells therapy is that T cells can naturally extravasate and
travel between endothelial barriers within tissue, unlike
monoclonal antibodies, which are limited by their size.
While the older bispecific constructs have the same disadvantage as mAbs, the newer formats can be made
smaller than a classical immunoglobulin allowing better
distribution but then usually have a reduced plasma
half-life (Brinkmann and Kontermann 2017). In terms of
duration of activity, limited data on genetically engineered CAR-T cells suggest that these cells may be able
to expand in vivo and result in prolonged response to
treatment if a memory pool is established (Caruana et al.
2014). Whether this is a long term advantage is unclear
as tumor recurrence lacking the target epitope has been
Table 5 Comparing bi-specific and tri-specific antibody therapy
to CAR T- cell therapy
Polyspecific antibodies

CAR T- cells

Polyspecific are antibodies with
T cells with genetically engineered
multiple specificities with one or
receptors that redirect them to a
more affinity sites towards tumor
chosen tumor antigen
antigens, and another one towards
an activator on immune effectors
(e.g. CD3 on T cells).
Highly efficient, rapid processCreated using multiple formats
including advanced protein
engineering and recombinant DNA
technologies and administered to
patients directly. Allows rapid
treatment of patients

Cumbersome, boutique process- T
cells from patients are collected,
antigen specific receptors (CARs)
are inserted invitro into T cells
using viral vectors, DNA
transposons, or RNA transfection
and then “expanded” in the
laboratory before reinfusing into
lyphodepleted patient. May delay
therapy for weeks.

When activated through CD3,
When CARs bind to tumor antigen,
cytotoxic T cells inject perforin and the intracellular signaling domain
granzyme B into target cells to kill. is activated and the tumoricidal
process by T cells is initiated.
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noted in hematological studies. On the contrary, the
short half-life of most engineered antibodies necessitates
multiple doses to ensure effective therapy but this has
been also improvised in some of the newer constructs by
adding a FC component or chemically modifying the
molecule.

Conclusions
Antibody-based cancer directed therapy is an exciting and
rapidly advancing field. The introduction of monoclonal
antibodies such as rituximab revolutionized cancer therapy and have given way to the creation of bi-specific and
tri-specific antibodies which work with more precision
and efficacy than their predecessors. The one currently
approved bi-specific antibody therapy, blinatumomab and
catumaxomab, have shown improved survival rates and
quality of life for subsets of cancer patients. Multiple
agents are currently being evaluated in clinical trials while
optimal structures and treatment algorithms are being defined to maximize benefit-risk ratio. Newer approaches
concurrently targeting checkpoint molecules and
cancer-specific antigens seem promising in preclinical
models and may change the landscape of cancer therapeutics (Junttila et al. 2014; Hong et al. 2018).
Several biological parameters are still missing in the
understanding of the tumor biology and its complex
microenvironment. Engineered polyspecific antibodies
will likely play a major role in oncotherapeutics as cancer research continues to climb to new heights.
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